Primecap Management Co. CA Purchases 9,200 Shares of Galapagos NV (NASDAQ:GLPG)

Primecap Management Co. CA raised its position in shares of Galapagos NV (NASDAQ:GLPGFree Report) by 1.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 678,877 shares of the biotechnology company’s stock after purchasing an additional 9,200 shares during the quarter. Primecap Management Co. CA owned 1.03% of Galapagos worth $27,596,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC bought a new stake in Galapagos during the fourth quarter valued at approximately $44,000. Quadrant Capital Group LLC grew its position in shares of Galapagos by 18.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 261 shares during the period. Signaturefd LLC increased its stake in shares of Galapagos by 78.6% in the 4th quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 867 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Galapagos by 357.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 1,770 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in Galapagos by 9.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 6,000 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GLPG. StockNews.com cut Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Bank of America reissued an “underperform” rating and issued a $31.00 target price (down from $41.00) on shares of Galapagos in a report on Thursday, March 28th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $38.00 price target on shares of Galapagos in a research report on Monday, April 22nd. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. According to data from MarketBeat, Galapagos currently has an average rating of “Hold” and an average price target of $34.50.

Read Our Latest Stock Analysis on GLPG

Galapagos Stock Down 1.4 %

Shares of GLPG traded down $0.38 during mid-day trading on Friday, hitting $27.27. 95,712 shares of the stock were exchanged, compared to its average volume of 98,749. Galapagos NV has a 52-week low of $27.21 and a 52-week high of $44.25. The firm has a 50-day moving average of $30.24 and a two-hundred day moving average of $35.43.

Galapagos (NASDAQ:GLPGGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.51. Galapagos had a negative return on equity of 2.60% and a negative net margin of 26.25%. The business had revenue of $67.79 million for the quarter, compared to analysts’ expectations of $69.04 million. As a group, equities analysts expect that Galapagos NV will post 0.35 earnings per share for the current fiscal year.

Galapagos Company Profile

(Free Report)

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Further Reading

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPGFree Report).

Institutional Ownership by Quarter for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.